Loading...
XCSE
ZEAL
Market cap4.85bUSD
Apr 03, Last price  
463.20DKK
1D
-0.47%
1Q
-35.13%
Jan 2017
334.93%
IPO
438.60%
Name

Zealand Pharma A/S

Chart & Performance

D1W1MN
P/E
—
P/S
522.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.99%
Rev. gr., 5y
-14.82%
Revenues
63m
-78.57%
59,921,00056,262,00025,319,00087,357,000142,284,000223,565,0006,574,000153,773,000187,677,000234,778,000139,775,00037,977,00041,333,000353,314,000292,567,00062,691,000
Net income
-1.08b
L+5.96%
-55,000,000-33,732,000-75,710,000-104,634,00013,377,00036,372,000-183,676,000-64,990,000-113,957,000-153,910,000-272,271,000581,282,000-571,541,000-846,729,000-1,018,149,000-1,078,828,000
CFO
-931m
L-23.20%
-57,572,000-28,622,000-61,454,000-55,980,000-1,806,00068,537,000-169,618,000-42,183,000-225,413,00040,904,000-278,746,000-460,400,000-409,455,000-688,716,000-1,211,971,000-930,816,000

Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
URL
https://www.zealandpharma.com/
IPO date
Nov 01, 2010
Employees
237
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
62,691
 
Cost of revenue
1,156,941
Unusual Expense (Income)
NOPBT
(1,094,250)
NOPBT Margin
Operating Taxes
(4,617)
Tax Rate
NOPAT
(1,089,633)
Net income
(1,078,828)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
8,171,645
BB yield
Debt
Debt current
16,036
Long-term debt
482,144
Deferred revenue
Other long-term liabilities
109,665
Net debt
(801,755)
Cash flow
Cash from operating activities
(930,816)
CAPEX
(10,053)
Cash from investing activities
(7,332,915)
Cash from financing activities
8,288,491
FCF
Balance
Cash
8,226,010
Long term investments
(6,926,075)
Excess cash
1,296,800
Stockholders' equity
(6,086,417)
Invested Capital
15,204,580
ROIC
ROCE
EV
Common stock shares outstanding
66,434
Price
Market cap
EV
EBITDA
(1,068,403)
EV/EBITDA
Interest
34,047
Interest/NOPBT